REG - Novacyt S.A. - Launch of LightBench® Discover

Novacyt SAAnnouncement

15/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250715:nRSO0152Ra&default-theme=true

RNS Number : 0152R  Novacyt S.A.  15 July 2025

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Launch of LightBench® Discover

 

Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular
diagnostics company with a broad portfolio of integrated technologies and
services, announces the launch of LightBench® Discover, a high-precision
3-in-1 instrument for genomic research labs conducting long-read sequencing.

 

The concept for the LightBench® Discover was developed following a close
collaboration with PacBio®, where Yourgene Health became a PacBio®
Compatible Partner for the original LightBench® in November 2023. As part of
product development for LightBench® Discover, Novacyt deployed prototype
instruments into the field to gather customer feedback on user experience,
develop protocols and run real world samples to assess the instruments'
performance.

 

LightBench® Discover is an integrated single benchtop solution that replaces
the need for multiple instruments in labs conducting long-read HiFi
sequencing, who need both large fragment analytics (larger than 20 kilobases)
and DNA size selection. In addition, LightBench® Discover also delivers
fluorometric quantification. Researchers benefit from a cost-effective,
high-performance system that enhances efficiency, whilst eliminating the need
to invest in multiple instruments with separate service contracts and software
platforms. The product has extended capabilities (compared to the original
LightBench®) for large fragment analytics up to 150 kilobases, along with
size selection and quantification functions, making it ideal for research
applications utilising long read sequencing on the PacBio Revio® or Vega™
systems.

 

Today, the Company has released the Technical Note showcasing data from its
collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in
Alabama, US. The Technical Note will be hosted on the Company's website
https://yourgenehealth.com/our-products/instruments/lightbench-discover/
(https://yourgenehealth.com/our-products/instruments/lightbench-discover/) and
on the PacBio® Compatible Partners webpage
https://www.pacb.com/3rd-party-compatible-products/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.pacb.com_3rd-2Dparty-2Dcompatible-2Dproducts_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=Sogm6exrd5UfoXbExUfyjF5KBBHLMFlO_mwm8T7SCoY&m=7ZwdEBoLwdCDaCT5KNwHNo12NFm7xOeAbtnUDyWpRnEwtqBuxodsRG7LDEfV0WeZ&s=S2hLpfcj4Rv4SoqWvexSwjedAZwKh8OerbjX3ryqiPE&e=)
.

 

Lyn Rees, CEO of Novacyt, commented: "The product development and launch of
LightBench® Discover is a significant achievement for the Novacyt team, and I
would like to congratulate everyone for their efforts. LightBench® Discover's
3-in-1 technology provides cost efficiencies, enhances quality control,
simplifies workflows and delivers high-accuracy analytics which have all been
designed around our customer needs. This new offering from Novacyt will only
further strengthen our existing partnerships and keep us at the forefront of
genomic research."

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·  Pharmaceutical research services: whole genome sequencing (WGS) / whole
                      exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries. The Company is listed on the London Stock Exchange's AIM
market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKQBPCBKDAOD